Breakthrough Device Designation: The Real FDA and Medicare Picture

2026-08-17 · Caduvo Team

Breakthrough Device Designation can speed FDA review, but it does not guarantee Medicare coverage. Here are the real criteria, benefits, and what Transitional Coverage for Emerging Technologies actually means for your device.

You have a device that treats a life-threatening condition, and no cleared alternative exists. Your path to market is long, but the FDA has a program that can shorten it. Breakthrough Device Designation promises interactive review and senior management attention. But then the reimbursement question hits: does designation mean Medicare will pay? Short answer: no. Here is what the program actually delivers, and what it does not.

What Qualifies for Breakthrough Device Designation

The FDA grants breakthrough designation to devices that meet two tests. First, the device must provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. Second, at least one of these must be true: the device represents a breakthrough technology, no approved or cleared alternatives exist, the device offers significant advantages over existing alternatives, or device availability is in the best interest of patients.

These criteria come straight from the 21st Century Cures Act and the FDA's 2018 final guidance. They are deliberately broad. A device does not need to be radical science. It needs to show a meaningful clinical benefit over what is currently available. For example, a new catheter that reduces infection risk in a high-mortality patient population could qualify, even if other catheters exist, because the infection reduction is a significant advantage.

The designation is not tied to a specific premarket pathway. Your device might go through a 510(k), a de novo, or a PMA. In practice, most breakthrough devices use the de novo pathway or a PMA because the "no predicate" or "significant advantage" criteria often rule out substantial equivalence. Designation can happen at any time before you submit your marketing application, but the FDA strongly recommends requesting it before or during your pre-submission meeting. The decision takes 60 days.

The Application Process: What to Submit

You request designation through the FDA's CDRH Portal using a Q-Submission. The package includes:

• A description of the device and its intended use.
• A summary of the disease or condition, including why it is life-threatening or irreversibly debilitating.
• A description of how the device meets the breakthrough criteria.
• Supporting data, whether preclinical, clinical, or literature-based.
• A proposed plan for clinical development.

The FDA does not require full clinical data at this stage, but you need a credible story. The review is substantive. Officials will look at your existing evidence and your development plan, then decide if the device plausibly meets the criteria. If you are missing key data, they may ask for more. A designation request is not a formality.

One common mistake: applying too late. Some founders wait until they have IDE approval or early clinical results. That forfeits months of interactive review. Designation is most valuable when you still have design choices to make, because the FDA will give you feedback on your clinical protocol and nonclinical testing plan.

Benefits During FDA Review

The program offers three concrete benefits: more frequent interaction, senior management involvement, and priority review.

Interactive review means you can schedule regular meetings with the review team. Instead of a single pre-submission meeting and then months of silence, you can get feedback on data requirements, clinical endpoints, and manufacturing questions. This reduces the risk of a surprise deficiency later.

Senior management involvement matters when you hit a disagreement with the review team. Designated devices get access to the Office of Product Evaluation and Quality management earlier than usual. If a reviewer is taking an unreasonable position, you can escalate faster.

Priority review means your marketing application gets looked at sooner. The FDA does not commit to a fixed timeline, but breakthrough devices typically go to the front of the queue. In practice, that can cut several months off the total review time compared to a non-designated device in the same program.

What designation does not give you: automatic approval. You still need to run the same clinical trials and meet the same safety and effectiveness standards. The FDA will not lower the evidence bar. A breakthrough device can still receive a Not Approvable letter if the data are weak.

The Reimbursement Picture After Approval

Here is where founders get confused. Breakthrough designation is an FDA program. Medicare coverage is a CMS decision. The two agencies are separate, and designation confers no payment rights.

After FDA marketing authorization, Medicare can cover a device in several ways. For durable medical equipment, a DME MAC can assign an HCPCS code and set a fee schedule amount. Your device might qualify for the DME fee schedule if it meets the definition of DME. For devices used in procedures, payment is often baked into an existing CPT code or a new technology add-on payment under the hospital inpatient prospective payment system.

The program that explicitly addresses novel device reimbursement is Transitional Coverage for Emerging Technologies (TCET). TCET is a CMS pathway for certain breakthrough devices. It does not guarantee coverage. Instead, it provides a pre-market evaluation of clinical evidence and, if CMS decides coverage is warranted, a time-limited national coverage determination that can lead to broader coverage as more evidence accumulates. TCET is voluntary and narrow: it applies to certain device categories, and CMS decides case by case.

The misconception to kill early: designation does not equal coverage. Not now, not later. Even with TCET, CMS may conclude that the evidence does not support coverage, or that coverage should be limited to a clinical study. You still need a reimbursement strategy.

What Founders Should Do Next

If your device meets the breakthrough criteria, apply early. The interactive review alone is worth the effort. But do not mistake faster FDA feedback for faster payment. Start your reimbursement planning on day one.

Three concrete moves:

1. Request a pre-submission meeting with the FDA before you request designation. Get their read on whether you meet the criteria and what data they want to see.
2. Map the likely payment pathway: which HCPCS or CPT code will cover the procedure, and which MAC or payer will decide coverage. If you are unclear on this, fix that before the FDA application is filed.
3. Look at TCET early, but treat it as a possible tool, not a promise. Understand the evidence CMS will want before you design your clinical trial, because retrofitting evidence is expensive.

Caduvo can help you identify which codes and coverage pathways are most likely for your device, based on current payer policies and past decisions for similar technologies, without running blind into the reimbursement wall.